Laxana Capsule 24 mg
Laxana Capsule 24 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
Lupristone is a locally-acting chloride-channel activator that increases intestinal secretion. In doing so, it increases intestinal motility, thus aiding the passage of stool and relieve the symptoms associated with chronic idiopathic constipation.
Laxana Capsule 24 mg acts by specifically activating ClC-2 chloride channels, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A action independent fashion. Activation of ClC-2 chloride channels causes an efflux of chloride ions into the lumen, which in turn leads to an efflux of sodium ions through a paracellular pathway to maintain isoelectric neutrality. As a result, water follows sodium into the lumen in order to maintain isotonic equilibrium, thereby increasing intestinal fluid secretion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Activation of ClC-2 chloride channels may also stimulate the recovery of muscosal barrier function by restoring tight junction protein complexes in the intestine. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.
Chronic idiopathic constipation is generally defined by infrequent or difficult passage of stool. The signs and symptoms associated with chronic idiopathic constipation (i.e., abdominal pain or discomfort, bloating, straining, and hard or lumpy stools) may be the result of abnormal colonic motility that can delay the transit of intestinal contents and impede the evacuation of rectal contents. One approach to the treatment of chronic idiopathic constipation is the secretion of fluid into the abdominal lumen through the activation of chloride channels in the apical membrane of the gastrointestinal epithelium. Laxana Capsule 24 mg is a locally acting chloride channel activator that increases intestinal chloride and fluid secretion without altering sodium and potassium concentrations in the serum.
Trade Name | Laxana Capsule 24 mg |
Availability | Prescription only |
Generic | Lubiprostone |
Lubiprostone Other Names | Lubiprostone |
Related Drugs | dicyclomine, MiraLAX, lactulose, Colace, docusate, Linzess, bisacodyl, Bentyl, senna, hyoscyamine |
Weight | 24 mg |
Type | Capsule |
Formula | C20H32F2O5 |
Weight | Average: 390.468 Monoisotopic: 390.221780456 |
Protein binding | 94% |
Groups | Approved, Investigational |
Therapeutic Class | Other laxative preparations |
Manufacturer | Renata Limited |
Available Country | Bangladesh |
Last Updated: | October 19, 2023 at 6:27 am |
Uses
Laxana Capsule 24 mg is used for Chronic Idiopathic Constipation, Opioid-induced Constipation (OIC) in adults with chronic non-cancer pain, Irritable Bowel Syndrome with Constipation (IBS-C).
Laxana Capsule 24 mg is also used to associated treatment for these conditions: Constipation, Opioid Induced Constipation (OIC), Chronic idiopathic constipation (CIC)
How Laxana Capsule 24 mg works
Laxana Capsule 24 mg acts by specifically activating ClC-2 chloride channels, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A action independent fashion. Activation of ClC-2 chloride channels causes an efflux of chloride ions into the lumen, which in turn leads to an efflux of sodium ions through a paracellular pathway to maintain isoelectric neutrality. As a result, water follows sodium into the lumen in order to maintain isotonic equilibrium, thereby increasing intestinal fluid secretion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Activation of ClC-2 chloride channels may also stimulate the recovery of muscosal barrier function by restoring tight junction protein complexes in the intestine. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.
Dosage
Laxana Capsule 24 mg dosage
Irritable Bowel Syndrome with Constipation:The recommended dose is 8 mcg twice daily orally with food and water.
Dosage in patients with hepatic impairment: Dosage adjustment is not required for patients with moderately impaired hepatic function. For patients with severely impaired hepatic function, the recommended starting dose is 8 mcg once daily. If tolerated then dose can be increased to 8 mcg twice
Chronic Idiopathic Constipation and Opioid-induced Constipation:The recommended dose is 24 mcg twice daily orally with food and water.
Dosage in patients with hepatic impairment: For patients with moderately impaired hepatic function, the recommended starting dose is 16 mcg twice daily. For patients with severely impaired hepatic function, the recommended starting dose is 8 mcg twice daily.
Side Effects
Diarrhea, full or bloated feeling or pressure in the stomach, nausea, stomach pain, swelling of abdominal or stomach area, Dyspnea
Toxicity
In a definitive Phase 1 cardiac repolarization study, 51 patients were administered a single oral dose of 144 mcg of lubiprostone, which is 6 times the normal single administration dose. Thirty-nine (39) of the 51 patients experienced an adverse event. The adverse events reported in >1% of this group included the following: nausea (45.1%), vomiting (27.5%), diarrhea (25.5%), dizziness (17.6%), loose or watery stools (13.7%), headache (11.8%), retching (7.8%), abdominal pain (5.9%), flushing or hot flush (5.9%), dyspnea (3.9%), pallor (3.9%), stomach discomfort (3.9%), syncope (3.9%), upper abdominal pain (2.0%), anorexia (2.0%), asthenia (2.0%), chest discomfort (2.0%), dry mouth (2.0%), hyperhidrosis (2.0%), skin irritation (2.0%) and vasovagal episode (2.0%).
Precaution
Nausea: Patients taking Laxana Capsule 24 mg may experience nausea. Concomitant administration of food with Laxana Capsule 24 mg may reduce symptoms of nausea.
Diarrhea: Lubistone should not be prescribed to patients that have severe diarrhea.
Bowel Obstruction: In patients with symptoms suggestive of mechanical gastrointestinal obstruction, perform a thorough evaluation to confirm the absence of an obstruction prior to initiating therapy with Laxana Capsule 24 mg.
Interaction
There is a possibility of a dose-dependent decrease in the efficacy of Laxana Capsule 24 mg in patients using diphenylheptane opioids.
Food Interaction
- Take with a full glass of water.
- Take with food. Taking lubiprostone with food may reduce nausea.
Laxana Capsule 24 mg Disease Interaction
Major: GI obstructionModerate: diarrhea, dyspnea, hepatic impairment
Elimination Route
Laxana Capsule 24 mg has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL).
Half Life
0.9 to 1.4 hours
Elimination Route
Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours. Laxana Capsule 24 mg and M3 are only detected in trace amounts in human feces.
Pregnancy & Breastfeeding use
Pregnancy category C. It is not known whether lubiprostone is excreted in human milk. Because lubiprostone increases fluid secretion in the intestine and intestinal motility, human milk-fed infants should be monitored for diarrhea. Caution should be exercised when Laxana Capsule 24 mg is administered to a nursing woman.
Contraindication
Laxana Capsule 24 mg is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Acute Overdose
Adverse reactions due to overdose may include: nausea, diarrhea, vomiting, dizziness, headache, abdominal pain, flushing/hot flash, retching, dyspnea, pallor, stomach discomfort, anorexia, asthenia , chest discomfort, dry mouth, hyperhidrosis , and syncope.
Storage Condition
Store between 15-30° C.
Innovators Monograph
You find simplified version here Laxana Capsule 24 mg
Laxana Capsule 24 mg contains Lubiprostone see full prescribing information from innovator Laxana Capsule 24 mg Monograph, Laxana Capsule 24 mg MSDS, Laxana Capsule 24 mg FDA label